UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

UCB SA ( UCBJY ) Bank of America Global Healthcare Conference 2026 September 23, 2026 6:45 AM EDT Company Participants Sandrine Dufour - Executive VP & CFO Conference Call Participants Charlie Haywood - BofA Securities, Research Division Presentation Charlie Haywood BofA Securities, Research Division Good morning, everyone. Hope you can hear me okay. Welcome to, I think, the last session before lunch. I'm Charlie Haywood from the Bank of America European Pharma team. My pleasure to be hosting Sandrine Dufour, UCB CFO. So welcome. Thank you for joining us today. Question-and-Answer Session Charlie Haywood BofA Securities, Research Division And I think -- yes, I think let's start big picture, any sort of opening intro remarks, how we're feeling about things. Obviously, a good start to the year. Lots of interesting stuff coming up, which I'm sure we'll dig into, but... Sandrine Dufour Executive VP & CFO I'm sure, yes. No. And thanks. Happy to start with just the big picture. So as you know, UCB is on this 10-year growth trajectory. And I think what makes UCB quite unique is that we have more than 10 years of exclusivity with our largest growth driver, which is BIMZELX. And you've seen talking about recent trends that building on last year growth, we've put out 1H numbers, which were quite strong for the first half, 27% growth, net sales, very strong EBITDA gross margin expansion. And we've also upgraded the financial guidance for the year, and we also came with revised peak sales expectations for BIMZELX at at least EUR 7 billion. So nice -- very nice start of the year. And I think the other part that we are also really focused on is to work on shaping the future growth beyond the current commercial growth. And so we continue to invest in